Milan Riddick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Milan Riddick has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Andres Jose Garcia
Georgia Institute of Technology
2 shared publications - Pranav P. Kalelkar
Woodruff School of Mechanical Engineering and Petit Institute for Bioengineering and Bioscience Georgia Institute of Technology 315 Ferst Dr. NW Atlanta GA 30332 USA
2 shared publications Dina A. Moustafa
Department of Pediatrics and Children's Healthcare of Atlanta Center for Cystic Fibrosis and Airway Diseases Research Emory University School of Medicine 1510 Clifton Road NE Atlanta GA 30322 USA
1 shared publication- Joanna B. Goldberg
Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine
1 shared publication - Nael A. McCarty
Division of Pulmonology, Asthma, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine, USA
1 shared publication
Latest Publications
- 7 January 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (10) , 2102539-e2102539
Bacteriophage‐Loaded Poly(lactic‐co‐glycolic acid) Microparticles Mitigate Staphylococcus aureus Infection and Cocultures of Staphylococcus aureus and Pseudomonas aeruginosa
Lung infections caused by Gram‐positive Staphylococcus aureus (S. aureus) and coinfections caused by S. aureus and Gram‐negative Pseudomonas aeruginosa (P. aeruginosa) are challenging to treat, especially with the rise in the number of antibiotic‐resistant strains of these pathogens. Bacteriophage (phage) are bacteria‐specific viruses that can infect and lyse bacteria, providing a potentially effective therapy for bacterial infections. However, the development of bacteriophage therapy is impeded by limited suitable biomaterials that can facilitate effective delivery of phage to the lung. Here, the ability of porous microparticles engineered from poly(lactic‐co‐glycolic acid) (PLGA), a biodegradable polyester, to effectively deliver phage to the lung, is demonstrated. The phage‐loaded microparticles (phage‐MPs) display potent antimicrobial efficacy against various strains of S. aureus in vitro and in vivo, and arrest the growth of a clinical isolate of S. aureus in the presence of sputum supernatant obtained from cystic fibrosis patients. Moreover, phage‐MPs efficiently mitigate in vitro cocultures of S. aureus and P. aeruginosa and display excellent cytocompatibility with human lung epithelial cells. Therefore, phage‐MPs represents a promising therapy to treat bacterial lung infection.
- 7 January 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (10) , 2102539-e2102539
Bacteriophage‐Loaded Poly(lactic‐co‐glycolic acid) Microparticles Mitigate Staphylococcus aureus Infection and Cocultures of Staphylococcus aureus and Pseudomonas aeruginosa
Lung infections caused by Gram‐positive Staphylococcus aureus (S. aureus) and coinfections caused by S. aureus and Gram‐negative Pseudomonas aeruginosa (P. aeruginosa) are challenging to treat, especially with the rise in the number of antibiotic‐resistant strains of these pathogens. Bacteriophage (phage) are bacteria‐specific viruses that can infect and lyse bacteria, providing a potentially effective therapy for bacterial infections. However, the development of bacteriophage therapy is impeded by limited suitable biomaterials that can facilitate effective delivery of phage to the lung. Here, the ability of porous microparticles engineered from poly(lactic‐co‐glycolic acid) (PLGA), a biodegradable polyester, to effectively deliver phage to the lung, is demonstrated. The phage‐loaded microparticles (phage‐MPs) display potent antimicrobial efficacy against various strains of S. aureus in vitro and in vivo, and arrest the growth of a clinical isolate of S. aureus in the presence of sputum supernatant obtained from cystic fibrosis patients. Moreover, phage‐MPs efficiently mitigate in vitro cocultures of S. aureus and P. aeruginosa and display excellent cytocompatibility with human lung epithelial cells. Therefore, phage‐MPs represents a promising therapy to treat bacterial lung infection.
- Top Cited Papers
- 15 September 2021
- Published by Springer Nature in Nature Reviews Materials
- Vol. 7 (1) , 39-54
Biomaterial-based antimicrobial therapies for the treatment of bacterial infections
The rise in antibiotic-resistant bacteria, including strains that are resistant to last-resort antibiotics, and the limited ability of antibiotics to eradicate biofilms have necessitated the development of alternative antibacterial therapeutics. Antibacterial biomaterials, such as polycationic polymers, and biomaterial-assisted delivery of non-antibiotic therapeutics, such as bacteriophages, antimicrobial peptides and antimicrobial enzymes, have improved our ability to treat antibiotic-resistant and recurring infections. Biomaterials not only allow targeted delivery of multiple agents but also sustained release at the infection site, thereby reducing potential systemic adverse effects. In this Review, we discuss biomaterial-based non-antibiotic antibacterial therapies for the treatment of community-acquired and hospital-acquired infectious diseases, with a focus on in vivo results. We highlight the translational potential of different biomaterial-based strategies and provide a perspective on the challenges associated with their clinical translation. Finally, we discuss the future scope of biomaterial-assisted antibacterial therapies.
- 15 September 2021
- Published by Springer Nature in Nature Reviews Materials
- Vol. 7 (1) , 39-54
Top Cited PapersBiomaterial-based antimicrobial therapies for the treatment of bacterial infections
The rise in antibiotic-resistant bacteria, including strains that are resistant to last-resort antibiotics, and the limited ability of antibiotics to eradicate biofilms have necessitated the development of alternative antibacterial therapeutics. Antibacterial biomaterials, such as polycationic polymers, and biomaterial-assisted delivery of non-antibiotic therapeutics, such as bacteriophages, antimicrobial peptides and antimicrobial enzymes, have improved our ability to treat antibiotic-resistant and recurring infections. Biomaterials not only allow targeted delivery of multiple agents but also sustained release at the infection site, thereby reducing potential systemic adverse effects. In this Review, we discuss biomaterial-based non-antibiotic antibacterial therapies for the treatment of community-acquired and hospital-acquired infectious diseases, with a focus on in vivo results. We highlight the translational potential of different biomaterial-based strategies and provide a perspective on the challenges associated with their clinical translation. Finally, we discuss the future scope of biomaterial-assisted antibacterial therapies.